ReproCELL Inc.
TTSE:4978121.00
JPY
-3.00
(-2.42%)
ISIN
JP3974770004
Return %
Stock
S&P 500
1Y
-35.29
14.20
3Y
-45.98
81.12
5Y
-51.79
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Chikafumi Yokoyama
- Full Time Employees
- 101
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- MetLife Shin-Yokohama Building Yokohama Japan 222-0033
- IPO Date
- Jun 26, 2013
- Website
- reprocell.co.jp
- Similar Companies
- Business
- ReproCELL Incorporated engages in the development and provision of stem cell technologies, research reagents, and contract research organization services for drug discovery and regenerative medicine. The company manufactures and sells stem cell reagents including RNA reprogramming kits, small molecules, growth factors and cytokines, antibodies, staining kits, cell substrates, cryopreservation media, dissociation solutions, transfection reagents, and feeder cells; differentiated induced pluripotent stem cell (iPSC) products such as cardiomyocytes, hepatocytes, neurons, and synfire induced neurons; 3D cell culture systems including Alvetex scaffold technology; labware; and GMP-grade iPSC and mesenchymal stem cell (MSC) master cell banks. ReproCELL Incorporated also offers research stem cell services including footprint-free iPSC reprogramming and differentiation; clinical stem cell services; StemEdit clinical gene editing with CRISPR-SNIPER technology; precision medicine; preclinical and drug discovery CRO services using human fresh tissue and bioengineered 3D tissues; clinical laboratory and diagnostic services; human tissue samples from its global biorepository; and genomic services. Founded in 2003 and headquartered in Yokohama, Japan, ReproCELL Incorporated operates globally through subsidiaries in the USA, UK, and India, serving pharmaceutical, biotechnology, and academic customers in stem cell research, drug development, and regenerative medicine. The company maintains clinical networks across the USA and Europe for human tissue testing and conducts clinical trials in Japan for regenerative therapies targeting neurodegenerative diseases such as spinocerebellar ataxia. Recent developments include the June 2024 inauguration of a new GMP bio-manufacturing laboratory by REPROCELL USA for clinical-grade hiPSCs and hMSCs; the October 2025 receipt of funding from the Maryland Stem Cell Research Fund to enhance GMP-grade CDMO and iMSC capabilities; the October 2025 launch of Alvetex Advanced, a next-generation 3D bioengineered tissue system; and the November 2025 commercial launch of StemEdit hypoimmune hiPSC lines using advanced gene-editing technologies. In April 2025, partner Steminent Biotherapeutics reported positive Phase II clinical trial results for Stemchymal in Taiwan and Japan, supporting REPROCELL's exclusive commercialization rights in Japan for spinocerebellar ataxia treatment; the June 2023 launch of Pharmacology-AI by REPROCELL Europe and May 2023 initiation of CDMO services for clinical MSC products further expanded its offerings.